The Conversation (0)
Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol “ENOB”
Dec. 05, 2018 09:02AM PST
Biotech Investing
Enochian Biosciences (OTCQB:ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to transform the lives of persons living with HIV and cancer patients, today announced that the Company has received confirmation that its application to list the Company’s common stock on the NASDAQ Capital Market has been approved by the NASDAQ …
Enochian Biosciences (OTCQB:ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to transform the lives of persons living with HIV and cancer patients, today announced that the Company has received confirmation that its application to list the Company’s common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market.
As quoted in the press release:
Enochian’s common stock is expected to begin trading on the NASDAQ Capital Market on December 10, 2018 under the ticker symbol “ENOB.” The Company’s common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol “ENOB” until market close on December 7, 2018.
“We believe that the uplisting to NASDAQ will help attract institutional investors, broaden our shareholder base and enhance trading liquidity. We are excited about this milestone and look forward to progressing our gene-modified cell therapy platform to treat infectious disease and cancer patients,” stated Eric Leire, MD, CEO.